Education
About Us
Working with TipRanks
Follow Us
Opthea Limited Sponsored ADR (OPT)
NASDAQ:OPT
RESEARCH TOOLSreports
OPT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.85 - $6.30
Previous CloseN/A
Volume12.29K
Average Volume (3M)0.00
Market Cap
$484.35M
Enterprise Value$4.09B
Total Cash (Recent Filing)$172.47M
Total Debt (Recent Filing)AU$141.65M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
Aug 28, 2025EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.87
Shares Outstanding153,910,920
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-18.69
Price to Sales (P/S)0.00
P/FCF Ratio-0.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1.00Price Target Upside-68.75% Downside
Rating ConsensusHold
Number of Analyst Covering0
Opthea Limited Sponsored ADR News
Bulls Say, Bears Say
Bulls Say
Bears Say
Clinical TrialsThe Phase 3 COAST trial of sozinibercept in combination with Eylea in wet age-related macular degeneration failed to meet its primary endpoint, which is a significant setback.
Financial SolvencyThe company could be required to pay four multiples of the amounts paid to the company upon termination of the Development Funding Agreement, which would have a material impact on its solvency.
Stock DowngradeAnalyst downgrades the stock to MP, and the price target moves significantly from $12 to $1.
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
<0.01% Mutual Funds
4.76% Other Institutional Investors
95.24% Public Companies and Individual Investors
OPT FAQ
What was Opthea Limited Sponsored ADR’s price range in the past 12 months?
Opthea Limited Sponsored ADR lowest stock price was $1.85 and its highest was $6.30 in the past 12 months.
What is Opthea Limited Sponsored ADR’s market cap?
Opthea Limited Sponsored ADR’s market cap is $484.35M.
When is Opthea Limited Sponsored ADR’s upcoming earnings report date?
Opthea Limited Sponsored ADR’s upcoming earnings report date is Aug 28, 2025 which is in 60 days.
How were Opthea Limited Sponsored ADR’s earnings last quarter?
Opthea Limited Sponsored ADR released its earnings results on Feb 27, 2025. The company reported -$0.866 earnings per share for the quarter, missing the consensus estimate of -$0.13 by -$0.736.
Is Opthea Limited Sponsored ADR overvalued?
According to Wall Street analysts Opthea Limited Sponsored ADR’s price is currently Overvalued.
Does Opthea Limited Sponsored ADR pay dividends?
Opthea Limited Sponsored ADR does not currently pay dividends.
What is Opthea Limited Sponsored ADR’s EPS estimate?
Opthea Limited Sponsored ADR’s EPS estimate is -0.06.
How many shares outstanding does Opthea Limited Sponsored ADR have?
Opthea Limited Sponsored ADR has 153,910,920 shares outstanding.
What happened to Opthea Limited Sponsored ADR’s price movement after its last earnings report?
Opthea Limited Sponsored ADR reported an EPS of -$0.866 in its last earnings report, missing expectations of -$0.13. Following the earnings report the stock price went down -2.609%.
Which hedge fund is a major shareholder of Opthea Limited Sponsored ADR?
Currently, no hedge funds are holding shares in OPT
Opthea Limited Sponsored ADR Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.00 (-68.75% Downside)
$1.00 (-68.75% Downside)
Hedge Fund Trend
Decreased
By 86.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
―
20 days / 200 days
Momentum
60.10%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.45%
Trailing 12-Months
Company Description
Opthea Limited Sponsored ADR
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
Technical Analysis
Cormedix
―
Sinovac Biotech
―
Urogen Pharma
―
Arvinas Holding Company
―
Cullinan Management
―